Clinical trial results:
A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder

Summary

EudraCT number	2017-000685-29
Trial protocol	Outside EU/EEA
Global end of trial date	01 November 2008

Results information

Result version number	v1 (current)
This version publication date	22 December 2021
First version publication date	22 December 2021

Trial information

Trial identification

Sponsor protocol code	B4Z-KL-LYEC

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT00568685
WHO universal trial number (UTN)	-
Other trial identifiers	Trial ID: 11710

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 877-CTLilly, EU_Lilly_Clinical_Trials@lilly.com
Scientific contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 8772854559, EU_Lilly_Clinical_Trials@lilly.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 November 2008
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	01 November 2008
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To assess graphically dose-response with atomoxetine, as measured by change from baseline to endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) total score

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 November 2007
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Korea, Republic of: 153
Worldwide total number of subjects	153
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	126
Adolescents (12-17 years)	27
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Not Applicable

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Atomoxetine 0.2 mg/kg/Day

Arm description:

Participants receive 0.2 milligrams Per Kilogram, Per Day (mg/kg/day) atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period.

Arm type	Experimental
Investigational medicinal product name	Atomoxetine
Investigational medicinal product code	
Other name	LY139603; Strattera
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants receive 0.2 mg/kg/day atomoxetine administered orally.

Arm title	Atomoxetine 0.5 mg/kg/Day

Arm description:

Participants receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period.

Arm type	Experimental
Investigational medicinal product name	Atomoxetine
Investigational medicinal product code	
Other name	LY139603; Strattera
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants receive 0.5 mg/kg/day atomoxetine administered orally.

Arm title	Atomoxetine 1.2 mg/kg/Day

Arm description:

Participants initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Participants will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days.

Arm type	Experimental

Investigational medicinal product name	Atomoxetine
Investigational medicinal product code	
Other name	LY139603; Strattera
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Participants receive 1.2 mg/kg/day atomoxetine administered orally.

Number of subjects in period 1	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day
Started	51	51	51
Completed	41	46	46
Not completed	10	5	5
Consent withdrawn by subject	7	2	2
Adverse event, non-fatal	2	3	3
Protocol deviation	1	-	-

Baseline characteristics

Reporting groups

Reporting group title	Atomoxetine 0.2 mg/kg/Day

Reporting group description:

Participants receive 0.2 milligrams Per Kilogram, Per Day (mg/kg/day) atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period.

Reporting group title	Atomoxetine 0.5 mg/kg/Day

Reporting group description:

Participants receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period.

Reporting group title	Atomoxetine 1.2 mg/kg/Day

Reporting group description:

Participants initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Participants will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days.

Reporting group values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day
Number of subjects	51	51	51
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age continuous Units: years			
geometric mean	8.87	10.06	9.29
inter-quartile range (Q1-Q3)	7.63 to 12.09	8.11 to 11.17	8.02 to 11.06
Gender categorical Units: Subjects			
Female	4	41	40
Male	47	10	11
Race/Ethnicity Units: Subjects			
Korean	51	51	51
ADHD Rating Scale-IV-Parent:Investigator Rated Hyperactivity Subscale Score			
Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) is an 18-item scale with one item for each of 18 symptoms contained			

in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnosis for ADHD. Hyperactive/Impulsive Subscale consists of 9 items. Each item is scored on a 4 point scale (0=never or rarely; 1=sometimes; 2=often; 3=very often) for total score range of 0 (no symptoms) to 27 (highly symptomatic).			
Units: Units on a Scale			
arithmetic mean	17.51	16.61	15.96
standard deviation	± 5.825	± 5.107	± 5.553

Reporting group values	Total		
Number of subjects	153		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age continuous			
Units: years			
geometric mean			
inter-quartile range (Q1-Q3)	-		
Gender categorical			
Units: Subjects			
Female	85		
Male	68		
Race/Ethnicity			
Units: Subjects			
Korean	153		

ADHD Rating Scale-IV-Parent:Investigator Rated Hyperactivity Subscale Score			
Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version:Investigator-Administered and Scored (ADHDRS-IV-Parent:Inv) is an 18-item scale with one item for each of 18 symptoms contained in the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnosis for ADHD. Hyperactive/Impulsive Subscale consists of 9 items. Each item is scored on a 4 point scale (0=never or rarely; 1=sometimes; 2=often; 3=very often) for total score range of 0 (no symptoms) to 27 (highly symptomatic).			
Units: Units on a Scale			
arithmetic mean			
standard deviation	-		

End points

End points reporting groups

Reporting group title	Atomoxetine 0.2 mg/kg/Day

Reporting group description:

Participants receive 0.2 milligrams Per Kilogram, Per Day (mg/kg/day) atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period.

Reporting group title	Atomoxetine 0.5 mg/kg/Day

Reporting group description:

Participants receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period.

Reporting group title	Atomoxetine 1.2 mg/kg/Day

Reporting group description:

Participants initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Participants will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days.

Subject analysis set title	0-0.35 mg/kg/Day
Subject analysis set type	Per protocol

Subject analysis set description:

Participants received atomoxetine 0-0.35 mg/kg/day

Subject analysis set title	0.36-0.85 mg/kg/Day
Subject analysis set type	Per protocol

Subject analysis set description:

Participants received atomoxetine 0.36-0.85 mg/kg/day

Subject analysis set title	>0.85 mg/kg/Day
Subject analysis set type	Per protocol

Subject analysis set description:

Participants received atomoxetine >0.85 mg/kg/day

Primary: Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score

End point title	Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHDRS-IV-Parent:Inv) Total Score

End point description:

Measures the 18 symptoms contained in the DSM-IV diagnosis of Attention-Deficit/Hyperactivity Disorder. Individual item scores range from 0 none/never or rarely) to 3 (severe/very often). Total scores range from 0 (no symptoms) to 54 (highly symptomatic).

Analysis Population Description (APD): Analysis included all randomized participants (intent-to-treat population)

End point type	Primary

End point timeframe:

Baseline, Day 42

End point values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51	51	51	
Units: units on a scale				
least squares mean (confidence interval 95%)	-9.55 (-12.03 to -7.07)	-12.31 (-14.76 to -9.85)	-14.51 (-16.99 to -12.04)	

Statistical analyses

Statistical analysis title	ADHDRS-IV-Parent:Inv
Comparison groups	Atomoxetine 0.2 mg/kg/Day v Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.024
Method	ANCOVA

Secondary: Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint

End point title	Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Severity Scale (CGI-ADHD-S) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint

End point description:

Measures severity of the participant's overall severity of ADHD symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).

APD: ITT population; last observation carried forward (LOCF)

End point type	Secondary

End point timeframe:

Baseline, Days 7, 14, 42

End point values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51	51	51	
Units: units on a scale				
geometric mean (standard deviation)				
Day 7	-0.24 (± 0.480)	-0.53 (± 0.612)	-0.30 (± 0.036)	

Day 14	-0.73 (± 0.736)	-0.90 (± 0.918)	-0.92 (± 0.786)	
Day 42	-1.04 (± 0.729)	-1.30 (± 1.121)	-1.56 (± 1.090)	
LOCF Endpoint	-0.98 (± 0.750)	-1.22 (± 1.119)	-1.54 (± 1.073)	

Statistical analyses

Statistical analysis title	CGI-ADHD-S
Comparison groups	Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day v Atomoxetine 0.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0048
Method	Mixed models analysis

Secondary: Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint

End point title	Change From Baseline in Clinical Global Impression-Attention Deficit Hyperactivity Disorder-Improvement Scale (CGI-ADHD-I) Score at Days 7, 14, 42, and Last Observation Carried Forward Endpoint

End point description:

Measures total improvement (or worsening) of a patient's ADHD symptoms from the beginning of treatment. (1=very much improved, 7=very much worsened)

End point type	Secondary

End point timeframe:

Baseline, Days 7, 14, 42

End point values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51	51	51	
Units: units on a scale				
geometric mean (standard deviation)				
Day 7	3.57 (± 0.645)	3.22 (± 0.642)	3.54 (± 0.813)	
Day 14	3.25 (± 0.729)	3.20 (± 0.957)	2.98 (± 0.721)	
Day 42	3.24 (± 0.970)	3.09 (± 0.952)	2.77 (± 0.973)	
LOCF Endpoint	3.29 (± 0.957)	3.16 (± 0.946)	2.80 (± 0.969)	

Statistical analyses

Statistical analysis title	CGI-ADHD-I
Comparison groups	Atomoxetine 0.2 mg/kg/Day v Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0153
Method	Mixed models analysis

Secondary: Adverse Events Leading to Discontinuation

End point title	Adverse Events Leading to Discontinuation

End point description:

Adverse Events (Preferred Term) leading to discontinuation by decreasing frequency
APD: As-treated population

End point type	Secondary

End point timeframe:

Baseline to Day 42

End point values	0-0.35 mg/kg/Day	0.36-0.85 mg/kg/Day	>0.85 mg/kg/Day	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	51	54	48	
Units: events				
number (not applicable)				
Anorexia	0	1	0	
Appendicitis	0	1	0	
Dizziness	0	1	0	
Dysphemia	0	0	1	
Irritability	1	0	0	
Sedation	0	0	1	
Decreased appetite	0	1	0	

Statistical analyses

Statistical analysis title	Adverse Events Leading to Discontinuation
Comparison groups	0-0.35 mg/kg/Day v 0.36-0.85 mg/kg/Day v >0.85 mg/kg/Day

Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.45
Method	Fisher exact

Secondary: Incidence of Completion of the Columbia Suicide-Severity Rating Scale, Suicide and Self-Harm Summary

End point title	Incidence of Completion of the Columbia Suicide-Severity Rating Scale, Suicide and Self-Harm Summary

End point description:

Columbia Suicide-Severity Rating Scale (C-SSRS) captures occurrence, severity & frequency of suicide-related thoughts & behaviors, via questions designed to solicit information to determine if a suicide-related thought or behavior occurred. The C-SSRS is not scored; recorded incidents are counted. C-SSRS was only required if an adverse event was reported that the investigator suspected to represent a suicidal thought or behavior. If the C-SSR was completed at a visit, the Self-Harm Supplement was also required. If a self-harm event was reported, the Self-Harm Follow-Up form was also required.

End point type	Secondary

End point timeframe:

Baseline to Day 42

End point values	0-0.35 mg/kg/Day	0.36-0.85 mg/kg/Day	>0.85 mg/kg/Day	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	51	54	48	
Units: participants				
number (not applicable)	0	0	0	

Statistical analyses

No statistical analyses for this end point

Secondary: Heart Rate Change From Baseline to Day 42 Endpoint

End point title	Heart Rate Change From Baseline to Day 42 Endpoint

End point description:

APD: ITT population

End point type	Secondary

End point timeframe:

Baseline, Day 42

End point values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51	51	51	
Units: beats per minute (bpm)				
geometric mean (standard deviation)				
Baseline	87.86 (± 12.324)	85.78 (± 10.769)	90.10 (± 12.852)	
Day 42	90.43 (± 10.278)	90.35 (± 11.028)	93.89 (± 13.287)	
Change at endpoint	2.59 (± 13.041)	5.24 (± 13.621)	4.98 (± 14.649)	

Statistical analyses

Statistical analysis title	Heart Rate Change
Comparison groups	Atomoxetine 0.2 mg/kg/Day v Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.8005
Method	ANOVA

Secondary: Temperature Change From Baseline to Day 42 Endpoint

End point title	Temperature Change From Baseline to Day 42 Endpoint

End point description:

APD: ITT population

End point type	Secondary

End point timeframe:

Baseline, Day 42

End point values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51	51	51	
Units: degrees Celsius				
geometric mean (standard deviation)				
Baseline	36.63 (± 0.260)	36.56 (± 0.397)	36.50 (± 0.400)	
Day 42	36.58 (± 0.331)	36.55 (± 0.332)	36.59 (± 0.270)	
Change at endpoint	-0.05 (± 0.343)	-0.02 (± 0.339)	0.07 (± 0.327)	

Statistical analyses

Statistical analysis title	Temperature Change
Comparison groups	Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day v Atomoxetine 0.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.4128
Method	ANOVA

Secondary: Blood Pressure Change From Baseline to Day 42 Endpoint

End point title	Blood Pressure Change From Baseline to Day 42 Endpoint

End point description:

APD: ITT population

End point type	Secondary

End point timeframe:

Baseline, Day 42

End point values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51	51	51	
Units: mmHg				
geometric mean (standard deviation)				
Systolic Baseline	105.98 (± 12.888)	102.49 (± 11.279)	106.12 (± 13.749)	
Systolic Day 42	107.82 (± 14.440)	104.98 (± 10.988)	108.48 (± 11.067)	
Systolic Change at Endpoint	0.98 (± 16.535)	2.35 (± 12.122)	1.72 (± 13.391)	
Diastolic Baseline	66.53 (± 10.567)	65.39 (± 11.742)	66.78 (± 11.524)	
Diastolic Day 42	67.45 (± 10.199)	68.78 (± 11.677)	70.02 (± 8.734)	
Diastolic Change at Endpoint	0.16 (± 13.201)	3.65 (± 12.058)	2.17 (± 13.200)	

Statistical analyses

Statistical analysis title	Systolic Change
Comparison groups	Atomoxetine 0.2 mg/kg/Day v Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.9761
Method	ANOVA

Statistical analysis title	Diastolic Change
Comparison groups	Atomoxetine 0.2 mg/kg/Day v Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6419
Method	ANOVA

Secondary: Weight Change From Baseline to Day 42 Endpoint

End point title	Weight Change From Baseline to Day 42 Endpoint
End point description:	
End point type	Secondary
End point timeframe: Baseline, Day 42	

End point values	Atomoxetine 0.2 mg/kg/Day	Atomoxetine 0.5 mg/kg/Day	Atomoxetine 1.2 mg/kg/Day	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	51	51	51	
Units: kilograms (kg)				
geometric mean (standard deviation)				
Baseline	35.67 (± 12.348)	35.54 (± 10.647)	35.48 (± 11.536)	
Day 42	36.10 (± 12.524)	35.72 (± 11.305)	36.39 (± 11.708)	
Change at Endpoint	0.37 (± 1.500)	-0.08 (± 1.155)	-0.15 (± 1.093)	

Statistical analyses

Statistical analysis title	Weight Change
Comparison groups	Atomoxetine 0.2 mg/kg/Day v Atomoxetine 0.5 mg/kg/Day v Atomoxetine 1.2 mg/kg/Day
Number of subjects included in analysis	153
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.2213
Method	ANOVA

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline, End of the study

Adverse event reporting additional description:

The participant flow module encompasses the 'intention-to-treat' population. All safety data is reported with 'as-treated' population.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	11.0

Reporting groups

Reporting group title	Atomoxetine 0.00-0.35 mg/kg/Day

Reporting group description:

Patients who received the actual dose range listed.

Reporting group title	Atomoxetine 0.36-0.85 mg/kg/Day

Reporting group description:

Patients who received the actual dose range listed.

Reporting group title	Atomoxetine >0.85 mg/kg/Day

Reporting group description:

Patients who received the actual dose range listed.

Serious adverse events	Atomoxetine 0.00-0.35 mg/kg/Day	Atomoxetine 0.36-0.85 mg/kg/Day	Atomoxetine >0.85 mg/kg/Day
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 51 (0.00%)	1 / 54 (1.85%)	1 / 48 (2.08%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Road traffic accident			
subjects affected / exposed	0 / 51 (0.00%)	0 / 54 (0.00%)	1 / 48 (2.08%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 51 (0.00%)	1 / 54 (1.85%)	0 / 48 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Atomoxetine 0.00-0.35 mg/kg/Day	Atomoxetine 0.36-0.85 mg/kg/Day	Atomoxetine >0.85 mg/kg/Day
Total subjects affected by non-serious adverse events			
subjects affected / exposed	15 / 51 (29.41%)	22 / 54 (40.74%)	27 / 48 (56.25%)
Nervous system disorders			
Dizziness			
subjects affected / exposed	1 / 51 (1.96%)	3 / 54 (5.56%)	0 / 48 (0.00%)
occurrences (all)	1	3	0
Somnolence			
subjects affected / exposed	0 / 51 (0.00%)	1 / 54 (1.85%)	4 / 48 (8.33%)
occurrences (all)	0	1	4
General disorders and administration site conditions			
Irritability			
subjects affected / exposed	2 / 51 (3.92%)	2 / 54 (3.70%)	4 / 48 (8.33%)
occurrences (all)	2	2	5
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 51 (0.00%)	5 / 54 (9.26%)	4 / 48 (8.33%)
occurrences (all)	0	5	5
Nausea			
subjects affected / exposed	2 / 51 (3.92%)	3 / 54 (5.56%)	2 / 48 (4.17%)
occurrences (all)	2	3	2
Psychiatric disorders			
Sleep disorder			
subjects affected / exposed	4 / 51 (7.84%)	0 / 54 (0.00%)	1 / 48 (2.08%)
occurrences (all)	4	0	1
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	3 / 51 (5.88%)	4 / 54 (7.41%)	2 / 48 (4.17%)
occurrences (all)	3	4	2
Metabolism and nutrition disorders			
Anorexia			
subjects affected / exposed	2 / 51 (3.92%)	2 / 54 (3.70%)	6 / 48 (12.50%)
occurrences (all)	2	2	6
Decreased appetite			

subjects affected / exposed occurrences (all)	1 / 51 (1.96%) 1	4 / 54 (7.41%) 4	6 / 48 (12.50%) 8

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported